Table 2 Characteristics of subjects taking placebo in the randomised placebo controlled trials of osteoarthristis (OA), grouped according to active treatments
No. of trialsNo. of patientsAge, yearsGender, F/MBMI, kg/m2Baseline pain, %
Acupuncture462363 (2.5)2.3 (0.6)29.4 (3.7)48.1 (4.6)
TENS49275.8 (10.5)3.2 (3.6)29.248.9 (23.4)
Laser411363.3 (2.5)3.1 (1.5)29.9 (0.5)34.9 (25.5)
Magnets926364.2 (3.8)1.9 (1.0)28.4 (1.3)50.5 (10.9)
Insole29663.8 (2.5)4.727.0 (2.1)46.6 (8.7)
Knee tape/sleeve12662.73.374.5
Spa12955.013.533.868.2
Vitamin, fish oil, milk etc516458.2 (3.4)2.1 (1.7)28.9 (0.8)47.1 (21.3)
Herbals1247858.2 (5.6)2.6 (2.9)28.2 (2.1)54.4 (19.7)
Topical herbals317561.6 (2.3)1.9 (0.7)30.556.3 (8.1)
Paracetamol (acetaminophen)578664.3 (3.82.0 (1.2)28.0 (1.4)56.0 (14.1)
NSAIDs27195760.5 (5.0)2.7 (2.0)28.7 (3.6)59.2 (15.6)
Coxibs30475562.7 (4.1)2.6 (1.1)30.3 (1.7)61.0 (12.3)
Topical NSAIDs1389663.8 (2.4)2.2 (1.0)28.8 (2.4)53.5 (13.3)
Opioids12129461.1 (3.2)2.1 (0.7)34.0 (1.0)62.3 (9.4)
Glucosamine11106960.4 (5.3)2.1 (1.1)28.4 (3.3)40.3 (8.5)
Chondroitin744262.5 (3.3)2.8 (1.6)27.8 (1.4)52.7 (12.1)
Avocado soybean unsaponifiable540664.9 (1.4)2.5 (1.8)26.4 (1.4)54.0 (2.2)
Bisphosphonates262261.9 (2.4)3.1 (2.5)30.0 (0.6)40.1 (5.2)
Diacerhein344863.9 (1.6)2.1 (1.4)28.3 (3.9)60.2 (12.7)
IA hyaluronan1593763.5 (5.0)2.3 (2.1)28.7 (2.2)55.8 (14.7)
IM glycosaminoglycan peptide47558.0 (3.1)5.7 (3.9)26.6 (0.6)45.3 (32.3)
IA glycosaminoglycan peptide412259.5 (7.6)4.5 (1.4)2760.7 (16.6)
IA steroids719164.6 (2.3)2.1 (1.3)29.6 (0.6)58.9 (12.4)
Antidepressants115460.02.263.0
Debridement and/or lavage215154.0 (2.8)1.2 (1.6)66 (9.2)
Total1931636462.0 (4.7)2.6 (1.9)29.0 (2.6)54.9 (15.2)
  • Values are mean (SD) unless otherwise specified.

  • BMI, body mass index; coxibs, cyclo-oxygenase 2 inhibitors; F, female; IA, intra-articular; IM, intramuscular; M, male; NSAID, non-steroidal anti-inflammatory drug; TENS, transcutaneous electrical nerve stimulator.